Insiders · BBOT

Caleb Tripp

Chief Financial Officer at BridgeBio Oncology Therapeutics, Inc. (BBOT)

Caleb Tripp has filed 1 insider report with the SEC since August 2025, as chief Financial Officer at BridgeBio Oncology Therapeutics, Inc. (BBOT). The latest filing, on August 11, 2025, reports a change in holdings at BridgeBio Oncology Therapeutics, Inc. (BBOT).

Filings
1
Companies
1
Bought on market
None
Sold on market
None

Companies where Caleb Tripp is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
BridgeBio Oncology Therapeutics, Inc. logo
BBOT
BridgeBio Oncology Therapeutics, Inc.
Chief Financial Officer$1.81Aug 11, 2025

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Other insiders at the same companies

Questions about Caleb Tripp

What is Caleb Tripp's role at BridgeBio Oncology Therapeutics, Inc.?
Caleb Tripp reports to the SEC as chief Financial Officer at BridgeBio Oncology Therapeutics, Inc. (BBOT), according to the latest filing on August 11, 2025.
Has Caleb Tripp bought or sold stock recently?
No open-market purchases or sales by Caleb Tripp are on file.
How do I get alerts when Caleb Tripp files?
Follow Caleb Tripp on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Caleb Tripp (SEC CIK 0002010981). Totals count each trade once, skipping amendments whose original is on file, from Aug 11, 2025 on. View on SEC EDGAR · Get this as JSON